AbbVie to report on two drugs at the ACR/ARPH meeting

AbbVie will be reporting on data from multiple studies of upadacitinib, an investigational oral JAK1-selective inhibitor, at this year’s ACR/ARPH meeting. The SELECT Phase 3 clinical program evaluated the safety and efficacy of upadacitinib in patients with moderate to severe rheumatoid arthritis in over 4,000 patients, and AbbVie hopes the data will support regulatory submission for the drug in this patient group.
They will also be reporting on new HUMIRA (adalimumab) studies which evaluated treatment across multiple rheumatic conditions, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis and uveitis. That data includes an analysis of long-term disease control in patients with juvenile idiopathic arthritis receiving HUMIRA treatment for up to six years, plus the long-term inhibition of radiographic progression and quality of life measures in patients with moderate to severe psoriatic arthritis taking HUMIRA.
Marek Honczarenko, M.D., Ph.D., vice president, global immunology development, AbbVie, said: “While additional treatments have come to market in recent decades, there continues to be a need to advance scientific research to support optimal disease management for patients living with rheumatic conditions. The data we’re presenting at this year’s ACR/ARHP meeting, featuring HUMIRA and pipeline medicines, illustrate our ongoing commitment to researching additional therapeutic options and advancing care for patients, as well as AbbVie’s leadership in immunology.”